HTA - OHE - Page 2

We found for

Insight
October 2022

The Economics of Antibiotics – Part 3: Creating a Healthy Global Market for New Antibiotics

Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies

A Case Study Analysis: Challenges in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases

How is Quality of Life Measured for Health Technology Assessments?

Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies

The Broader Value of Vaccines: The Return on Investment From a Governmental Perspective

Health Technology Assessment…

Realising the Broader Value of Vaccines in the UK

International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making

Are Cost-Effectiveness Thresholds fit for Purpose for Real-World Decision Making?

HTA and Payment Mechanisms for New Drugs to Tackle AMR

Early Experience with Health Technology Assessment of Gene Therapies in the United States: Pricing and Paying for Cures

Issues Surrounding the Estimation of the Opportunity Cost of Adopting a New Health Care Technology: Areas for Further Research

Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence

Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help?

Additional Elements of Value for Health Technology Assessment Decisions

HTA and Decision Making in Asia: How can the available resources be used most effectively to deliver high quality HTA that can be used by health system decision makers?

01
02
03
04
05

News & Insights

Latest Research & Publications

All Publications

We found for

Filter results by

The Economics of Antibiotics – Part 3: Creating a Healthy Global Market for New Antibiotics

Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies

A Case Study Analysis: Challenges in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases

How is Quality of Life Measured for Health Technology Assessments?

Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies

The Broader Value of Vaccines: The Return on Investment From a Governmental Perspective

Realising the Broader Value of Vaccines in the UK

International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making

Are Cost-Effectiveness Thresholds fit for Purpose for Real-World Decision Making?

HTA and Payment Mechanisms for New Drugs to Tackle AMR

Early Experience with Health Technology Assessment of Gene Therapies in the United States: Pricing and Paying for Cures

Issues Surrounding the Estimation of the Opportunity Cost of Adopting a New Health Care Technology: Areas for Further Research

Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence

Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help?

Additional Elements of Value for Health Technology Assessment Decisions

HTA and Decision Making in Asia: How can the available resources be used most effectively to deliver high quality HTA that can be used by health system decision makers?